Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patient...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-04-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-021-01489-4 |
| _version_ | 1818446494486757376 |
|---|---|
| author | Xiyue Zhang Wei Li Chunyan Li Jie Zhang Zhenzhong Su |
| author_facet | Xiyue Zhang Wei Li Chunyan Li Jie Zhang Zhenzhong Su |
| author_sort | Xiyue Zhang |
| collection | DOAJ |
| description | Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function. |
| first_indexed | 2024-12-14T19:48:37Z |
| format | Article |
| id | doaj.art-a00aa405aaf2453c9feb7393b60b20d2 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-12-14T19:48:37Z |
| publishDate | 2021-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-a00aa405aaf2453c9feb7393b60b20d22022-12-21T22:49:30ZengBMCBMC Pulmonary Medicine1471-24662021-04-012111410.1186/s12890-021-01489-4Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung functionXiyue Zhang0Wei Li1Chunyan Li2Jie Zhang3Zhenzhong Su4Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin UniversityDepartment of Respiratory and Critical Care Medicine, The Second Hospital of Jilin UniversityDepartment of Respiratory and Critical Care Medicine, The Second Hospital of Jilin UniversityDepartment of Respiratory and Critical Care Medicine, The Second Hospital of Jilin UniversityDepartment of Respiratory and Critical Care Medicine, The Second Hospital of Jilin UniversityAbstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function.https://doi.org/10.1186/s12890-021-01489-4Small-cell lung cancerIdiopathic pulmonary fibrosisChemotherapy |
| spellingShingle | Xiyue Zhang Wei Li Chunyan Li Jie Zhang Zhenzhong Su Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function BMC Pulmonary Medicine Small-cell lung cancer Idiopathic pulmonary fibrosis Chemotherapy |
| title | Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function |
| title_full | Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function |
| title_fullStr | Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function |
| title_full_unstemmed | Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function |
| title_short | Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function |
| title_sort | chemotherapy in idiopathic pulmonary fibrosis and small cell lung cancer with poor lung function |
| topic | Small-cell lung cancer Idiopathic pulmonary fibrosis Chemotherapy |
| url | https://doi.org/10.1186/s12890-021-01489-4 |
| work_keys_str_mv | AT xiyuezhang chemotherapyinidiopathicpulmonaryfibrosisandsmallcelllungcancerwithpoorlungfunction AT weili chemotherapyinidiopathicpulmonaryfibrosisandsmallcelllungcancerwithpoorlungfunction AT chunyanli chemotherapyinidiopathicpulmonaryfibrosisandsmallcelllungcancerwithpoorlungfunction AT jiezhang chemotherapyinidiopathicpulmonaryfibrosisandsmallcelllungcancerwithpoorlungfunction AT zhenzhongsu chemotherapyinidiopathicpulmonaryfibrosisandsmallcelllungcancerwithpoorlungfunction |